Eloxx Pharmaceuticals (ELOX) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on small molecule therapies that modulate the ribosome to promote readthrough of premature stop codons caused by nonsense mutations (NMs), targeting rare genetic diseases.

• Lead candidate exaluren is being developed for rare kidney diseases, notably Alport syndrome with nonsense mutations (NMAS), and preclinical work is ongoing for autosomal dominant polycystic kidney disease (ADPKD) with NMs.

• ZKN-013, an oral ribosome modulating agent, is licensed to Almirall for rare skin diseases, with the company eligible for milestone and royalty payments.

Financial performance and metrics

• Reported net losses of $6.0M (2025), $3.1M (2024), and $17.1M (2023); accumulated deficit of $304.3M as of March 31, 2026.

• License and service revenue of $6.4M in 2024 from the Almirall agreement; no product sales to date.

• Cash and cash equivalents of $6.4M as of March 31, 2026; recurring losses raise substantial doubt about ability to continue as a going concern.

Use of proceeds and capital allocation

• Estimated net proceeds of $54.2M from the offering, assuming midpoint pricing.

• Proceeds allocated to advance exaluren clinical development for NMAS (Phase 2b) and nmADPKD (Phase 2), with remaining funds for working capital and general corporate purposes.

• Cash runway expected into mid-2028 based on current plans and offering proceeds.